咨詢熱線
15000266580
熱門關(guān)鍵詞：ATCC 細(xì)胞,細(xì)胞系,細(xì)胞株,腫瘤細(xì)胞,細(xì)胞,ATCC 菌種，CMCC 菌種，標(biāo)準(zhǔn)菌株，質(zhì)控菌種，微生物菌種，菌株，菌種
當(dāng)前位置：首頁 >產(chǎn)品中心>細(xì)胞系>人源細(xì)胞系>HTB-19BT-20細(xì)胞， 人乳癌細(xì)胞
簡要描述：BT-20細(xì)胞， 人乳癌細(xì)胞ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和*培養(yǎng)條件！
產(chǎn)品型號：HTB-19廠商性質(zhì)：生產(chǎn)廠家 更新時間：2026-03-22訪 問 量：2308 產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
BT-20細(xì)胞， 人乳癌細(xì)胞
| ATCC® Number: | HTB-19™ | Price: | |
| Designations:BT-20Depositors:EY LasfarguesBiosafety Level:1Shipped:frozenMedium & Serum:See PropagationGrowth Properties:adherentOrganism:Homo sapiensMorphology:epithelial Source:Organ: mammary gland; breast Disease: carcinomaPermits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.Isolation:Isolation date: 1958Applications:BT-20 cells are negative for estrogen receptor, but do express an estrogen receptor mRNA that has deletion of exon 5. This breast tumor line was established by E.Y. Lasfargues and L. Ozzello in 1958 by isolation and c*tion of cells spilling out of the tumor when it was cut in thin slices.Tumorigenic:YesBT-20細(xì)胞， 人乳癌細(xì)胞Reverse Transcript:negativeAntigen Expression:HLA A1, Bw16 (+/-)DNA Profile (STR):Amelogenin: X CSF1PO: 12 D13S317: 11 D16S539: 11,14 D5S818: 12 D7S820: 10 THO1: 7,9.3 TPOX: 11 vWA: 16,17Cytogenetic Analysis:Normal chromosomes N3, N4, N9, N13, N14, and X may be absent. The markers der(11)t(11;?)(q25;?) (M1); der(1)t(1;3)(p22?;p13?) (M2); and der(2)t(2;?) (q37;?) (M5) were detected by W.A. Nelson-Rees, et al., Int. J. Cancer 16: 74-85, 1975.Isoenzymes:AK-1, 1-2 ES-D, 1 G6PD, B GLO-I, 1-2 PGM1, 1 PGM3, 1Age:74 yearsGender:femaleEthnicity:CaucasianComments:The cells express the WNT3 and the WNT7B oncogenes [PubMed: 8168088]. This breast tumor line was established by E.Y. Lasfargues and L. Ozzello in 1958 by isolation and c*tion of cells spilling out of the tumor when it was cut in thin slices. A mycoplasma contaminant was discovered and eliminated early in 1972. Growth of BT-20 cells is inhibited by tumor necrosis factor alpha (TNF alpha). BT-20 cells are negative for estrogen receptor, but do express an estrogen receptor mRNA that has deletion of exon 5.Propagation:ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°CSubculturing:Protocol:Remove and discard culture medium.Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.Add appropriate aliquots of the cell suspension to new culture vessels.Incubate cultures at 37°C.Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:4 is recommended Medium Renewal: 2 to 3 times per weekPreservation:Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phaseRelated Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003recommended serum:ATCC 30-2020References:21405: Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 393311122536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 83387123079: Lan MS, et al. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res. 50: 2997-3001, 1990. PubMed: 233490323110: Castles CG, et al. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 53: 5934-5939, 1993. PubMed: 826140623113: Huguet EL, et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 54: 2615-2621, 1994. PubMed:816808823212: Lasfargues EY, Ozzello L. C*tion of human breast carcinomas. J. Natl. Cancer Inst. 21: 1131-1147, 1958. PubMed: 1361153723226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 701721232275: Littlewood-Evans AJ, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 939376432488: Geiger T, et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13: 35-45, 1998. PubMed: 9474241
| |||
產(chǎn)品咨詢
郵箱：xiangfbio@163.com
地址：上海市虹口區(qū)四平路710號7層
掃一掃 微信咨詢
